Nick Abbott
Stock Analyst at Wells Fargo
(0.09)
# 4,781
Out of 5,088 analysts
27
Total ratings
11.8%
Success rate
-43.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Nick Abbott
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CLLS Cellectis | Rated: Hold | $16 → $3 | $1.17 | +156.41% | 2 | Sep 15, 2026 | |
| ADAPY Adaptimmune Therapeutics plc | Reiterated: Hold | $1.5 | $0.0261 | n/a | 1 | Oct 4, 2022 | |
| AFMDQ Affimed N.V. | Initiated Coverage: Buy | $18 → $8 | $0.003 | n/a | 3 | Aug 18, 2022 | |
| IOVA Iovance Biotherapeutics | Initiated Coverage: Hold | $25 → $14 | $9.56 | n/a | 2 | Aug 18, 2022 | |
| STRO Sutro Biopharma | Initiated Coverage: Buy | $30 → $15 | $9.14 | n/a | 2 | Aug 18, 2022 | |
| CALA Calithera Biosciences, Inc. | Reiterated: Hold | $40 | $0.0001 | n/a | 1 | May 11, 2022 | |
| TCRT Alaunos Therapeutics | Upgraded: Buy | $3 | $1.89 | n/a | 2 | May 4, 2022 | |
| ZYME Zymeworks | Reiterated: Buy | $45 | $28.71 | n/a | 2 | May 3, 2022 | |
| PGEN Precigen | Reiterated: Buy | $17 | $6.64 | n/a | 3 | Apr 13, 2022 | |
| ARCT Arcturus Therapeutics Holdings | Reiterated: Buy | $107 → $105 | $12.15 | n/a | 3 | Mar 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgraded: Hold | $13 → $2 | $1.17 | n/a | 2 | Mar 25, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | n/a | $2.17 | n/a | 2 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $0.000001 | n/a | 1 | Jul 28, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $145 | $222.76 | n/a | 1 | Jun 29, 2021 |
Cellectis
Sep 15, 2026
Rated: Hold
Price Target: $16 → $3
Current: $1.17
Upside: +156.41%
Adaptimmune Therapeutics plc
Oct 4, 2022
Reiterated: Hold
Price Target: $1.5
Current: $0.0261
Upside: n/a
Affimed N.V.
Aug 18, 2022
Initiated Coverage: Buy
Price Target: $18 → $8
Current: $0.003
Upside: n/a
Iovance Biotherapeutics
Aug 18, 2022
Initiated Coverage: Hold
Price Target: $25 → $14
Current: $9.56
Upside: n/a
Sutro Biopharma
Aug 18, 2022
Initiated Coverage: Buy
Price Target: $30 → $15
Current: $9.14
Upside: n/a
Calithera Biosciences, Inc.
May 11, 2022
Reiterated: Hold
Price Target: $40
Current: $0.0001
Upside: n/a
Alaunos Therapeutics
May 4, 2022
Upgraded: Buy
Price Target: $3
Current: $1.89
Upside: n/a
Zymeworks
May 3, 2022
Reiterated: Buy
Price Target: $45
Current: $28.71
Upside: n/a
Precigen
Apr 13, 2022
Reiterated: Buy
Price Target: $17
Current: $6.64
Upside: n/a
Arcturus Therapeutics Holdings
Mar 25, 2022
Reiterated: Buy
Price Target: $107 → $105
Current: $12.15
Upside: n/a
Mar 25, 2022
Downgraded: Hold
Price Target: $13 → $2
Current: $1.17
Upside: n/a
Aug 23, 2021
Reiterated: Buy
Price Target: n/a
Current: $2.17
Upside: n/a
Jul 28, 2021
Upgraded: Buy
Price Target: n/a
Current: $0.000001
Upside: n/a
Jun 29, 2021
Reiterated: Hold
Price Target: $145
Current: $222.76
Upside: n/a